Jiangsu Recbio Technology Co., Ltd. (FRA:G93)

Germany · Delayed Price · Currency is EUR

0.5150

+0.0150 (3.00%)

At close: Jun 25, 2026

-40.12% (1Y)

Market Cap	323.45M -27.6%
Revenue (ttm)	1.55M
Net Income	-74.33M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.5150
Previous Close	0.5000
Day's Range	0.5150 - 0.5150
52-Week Range	0.0635 - 0.8950
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial; REC602, recombinant HPV bivalent vaccines targeting HPV type 6/11... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2011

Employees 491

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol G93

Financial Performance

Financial numbers in CNY Financial Statements